Trials / Completed
CompletedNCT00758862
The Pharmacokinetics of 2% TD1414 Cream in Adults With Secondarily Infected Traumatic Lesions (SITL) or Impetigo
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- LEO Pharma · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
A national, prospective single arm phase II study investigating the pharmacokinetics and safety of the 2% TD1414 cream when applied 3 times daily for 7 days to adult patients with impetigo or Secondarily Infected Traumatic Lesions (SITL). A total of 20 patients will be enrolled.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 2% TD1414 Cream | Application 3 times daily for 7 days |
Timeline
- Start date
- 2008-12-01
- Primary completion
- 2009-02-01
- Completion
- 2009-02-01
- First posted
- 2008-09-25
- Last updated
- 2025-03-13
- Results posted
- 2018-07-23
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00758862. Inclusion in this directory is not an endorsement.